



UNITED STATES PATENT AND TRADEMARK OFFICE

JAN -7 2008

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

Office of Regulatory Policy  
HFD-7  
5600 Fishers Lane (Rockwall II Rm 1101)  
Rockville, MD 20857


Attention: Beverly Friedman

The attached application for patent term extension of U.S. Patent No. 5,932,730 was filed on August 7, 2007, under 35 U.S.C. § 156. It is noted that applicant also filed applications for patent term extension for NDA 22-081 in U.S. Patent Nos. 5,703,017, 5,840,722, and 7,109,205, pursuant to 37 CFR 1.785.

The assistance of your Office is requested in confirming that the product identified in the application, LETAIRIS™(ambrisentan), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Inquiries regarding this communication should be directed to Raul Tamayo at (571) 272-7728 (telephone) or (571) 273-7728 (facsimile).



Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Martin L. Katz  
Wood, Phillips, Katz, Clark & Mortimer  
Citigroup Center, Suite 3800  
500 West Madison Street  
Chicago, IL 60661-2511